CTLA4 and melanoma: Anti-CTLA-4-blocking monoclonal antibodies Ipilimumab and Tremelimumab have already been tested in many clinical trials, both in melanoma patients and in patients with other malignancies [166-175] (see also http://www.clinicaltrials.gov/).